Navigation Links
Test Drug Seen as Best Hope in Decades for Tackling Parkinson's

A drug tested on lab mice slows and may even halt the progress of Parkinson's, offering the brightest pharmacological hope in decades of rolling back this tragic disease, US researchers report on Sunday.

Isradipine, already licensed for treatment for high blood pressure, rejuvenated ageing dopamine cells, the brain cells whose death causes Parkinson's, they say.

The outcome among mice was so promising that the team now plan on conducting trials on human volunteers.

"Our hope is that this drug will protect dopamine neurons, so that if you began taking it early enough, you won't get Parkinson's disease, even if you were at risk," said lead researcher James Surmeier, professor of physiology at Northwestern University in Chicago.

"It would be like taking a baby aspirin every day to protect your heart." Parkinson's is an incurable, degenerative disease of the central nervous system that causes uncontrollable shaking, along with impaired speech and movement.

In approximately one third of cases it also results in dementia.

Estimates of its prevalence vary between 0.1 and 0.3 percent of the population, meaning that approximately one in 500 people contract the disease.

The cause is a loss of dopamine, a chemical messenger that helps direct movement.

The substance is provided in a part of the brain called the substantia nigra.

Most pacemaking neurons use sodium ions to produce a regular electrical signal.

But the new research unexpectedly found that dopamine cells, when they reached adulthood, start to depend more and more on calcium ions.

This discovery is important, because calcium ions are far more troublesome to control than their placid sodium counterparts: the cell uses up lots of energy, either to round up and sequester the calcium or pump it out.

As a result, the dopamine cells become stressed on reaching their calcium-addicted adulthoo d and die prematurely.

Surmeier's hunch was to try isradipine, a well-tolerated hypertension and stroke drug commercialised under the name of DynaCirc, which blocks the channels in the cell surface that admit calcium.

Tested on lab-dish cells and then on mice which had been genetically engineered to have Parkinson's, the team found that within a few hours of being exposed to the drug, the neurons reverted to their youth-like state, of using sodium.

This lowered the cells' stress level, making them less vulnerable to the toxins, still poorly understood, that kills them.

"They start acting like they're youngsters again," Northwestern quoted Surmeier as saying.

The study is published online on Sunday by Nature, the British science journal.

So far the work has only been carried out on animals, and more needs to be done to assess the drug's effect on humans.

But Surmeier voiced cautious hopes it could be the first treatment to prevent or slow the progression of this devastating disease.

The mainstay treatment for Parkinson's is L-DOPA, a drug that the brain converts into dopamine.

At first, L-DOPA has a seemingly miraculous effective on symptoms.

The problem, though, is that it becomes less and less effective as time wears on and the disease progresses.

That forces doctors to raise the dose of this drug, which induces unwanted side-effects, including spastic, jerky movements.

So, if isradipine can slow the death of dopamine neurons, the L-DOPA "honeymoon" could be significantly extended.

"If we could double or triple the therapeutic window for L-DOPA, it would be a huge advance," said Surmeier.

"There has not been a major advance in the pharmacological management of Parkinson's in 30 years."


'"/>




Related medicine news :

1. Hope for First New Melanoma Treatment in Decades
2. Mentally Ill Man Spent Two Decades in Chains
3. Bubonic Plague Confirmed In L.A. After More Than Two Decades
4. Survivors of Childhood Polio Do Well Decades Later As They Age
5. Testosterone Levels in Men Decline Over Past Two Decades
6. Tackling Prostate Cancer With A New Dietary Supplement
7. Ways Of Tackling Antibiotic Resistance
8. Tackling Drug Addition in UK
9. Tackling of Cannabis Addiction
10. Heart Disease Can Be Avoided By Tackling The Cholesterol Early
11. WHO Praises Singapore and Vietnam but Slams China With Respect To Tackling SARS
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... ... 2016 , ... Texas Premier Locksmith , a leading ... unethical locksmith companies and is urging Search Engines to improve verification methods in ... Locksmith, these fraudulent locksmith services take advantage of consumers locked out of houses, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from My Life's ... reader to be aware of God's direction in their lives. “Walking With God: Inspirational ... teacher and active church leader. , Sanford says, “I enjoy sharing the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... YORK , Dec. 7, 2016 ... report on pulmonary drugs studies the current as ... The stakeholders of this report include companies and ... various pulmonary/respiratory drugs and/or drug-device combinations as well ... This report comprises an elaborate executive summary along ...
(Date:12/7/2016)... , Dec. 7, 2016  The Corporate Whistleblower ... manager to call them anytime at 866-714-6466 if they ... to sell more drugs. Aside from the innocent patients ... as well, because often-times these practices target Medicare recipients or ... ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
Breaking Medicine Technology: